“We have been working closely with the FDA to comprehensively evaluate the data following the reversible cardiac observations in the healthy volunteer trial and are committed to determining the best path forward for our programs, patients and the broader PWS community,” said Tien Lee, Founder and Chief Executive Officer of Aardvark. “We remain focused on establishing a clear path forward for the Phase 3 HERO trial evaluating ARD-101 in PWS, our lead program, and look forward to providing an update in the second quarter.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AARD:
- Options Volatility and Implied Earnings Moves Today, April 06, 2026
- Options Volatility and Implied Earnings Moves This Week, April 06 – April 10, 2026
- AARD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Aardvark Therapeutics price target lowered to $8 from $32 at B. Riley
- Aardvark Therapeutics Establishes $150 Million Equity Program